AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie is positioned as the preferred 2026 investment based on expectations for sales to rise to $67.2B and net income to surge to $14.6B from $4.2B in FY2025, supported by Skyrizi, Rinvoq and its proposed Apogee Therapeutics acquisition. Novo Nordisk generated stronger FY2025 profitability, with $48.2B of revenue and nearly $16B of net income for a 33% margin, and trades more cheaply at 13.8x forward earnings versus AbbVie's 16.1x. However, Novo faces projected FY2026 sales and net-income declines of about 3% and 4%, respectively, amid U.S. GLP-1 price reductions, competitive pressure from Eli Lilly and generic risks.

Analysis

ABBV’s investable issue is not distributor concentration but whether Skyrizi/Rinvoq can sustain enough volume and indication expansion to outrun the post-Humira revenue hole while absorbing acquisition financing and deal-related amortization. The market will likely reward a clean 2026 earnings bridge, but that creates a higher bar: upside requires durable operating-margin conversion rather than merely a favorable comparison against a depressed base. Any Apogee transaction should be treated as unverified until definitive terms, financing, and antitrust timing are disclosed; biotech M&A can dilute near-term EPS even when strategically sound.

NVO’s weaker near-term estimate trajectory may be a better contrarian setup than its headline growth profile implies. Pricing concessions and GLP-1 competition shift value from branded drug manufacturers toward scale manufacturers, device/component suppliers and, potentially, PBMs, but oral GLP-1 adoption could expand the treated population faster than price erosion if adherence and access improve. LLY is the principal competitive read-through: relative prescription trends, net-price realization, and supply availability matter more than reported revenue growth over the next 1-3 months.

The clean relative expression is ABBV versus NVO, not an outright healthcare beta bet. ABBV has a nearer earnings-validation catalyst; NVO has a 6-18 month optionality case if oral uptake and next-generation products stabilize growth before consensus resets lower. Falsification for ABBV is slowing combined immunology growth or reduced long-term guidance; for NVO, it is persistent share loss to LLY combined with gross-margin deterioration beyond the current estimate reset.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long ABBV / short NVO in equal dollar amounts. Target 10-15% relative return if ABBV delivers its earnings bridge while NVO estimates continue to reset; exit if ABBV’s combined Skyrizi/Rinvoq growth decelerates materially or NVO prescription/share data improve for two consecutive monthly reads.
• Use LLY as the confirmation hedge rather than a standalone chase: maintain or add LLY only after evidence of sustained U.S. GLP-1 share gains or supply normalization. The catalyst window is the next prescription-data cycle and earnings update; a reversal in share momentum would weaken the NVO short leg.
• Do not underwrite ABBV’s M&A upside until Apogee deal terms are independently confirmed. Set an alert for consideration mix, incremental net debt, pro forma EPS accretion timing, and FTC/Hart-Scott-Rodino milestones; cash-heavy financing or delayed closing would reduce the attractiveness of the long.
• For a 6-18 month reversal watch, accumulate NVO only if management demonstrates that oral Wegovy uptake offsets net-price pressure and protects gross margin. A valuation discount is not sufficient by itself; require upward revisions to 2027 sales or EPS consensus before converting the tactical short into a strategic long.